ed quarter. Meanwhile, Novo Nordisk gained after Bloomberg reported it expects generic competition to its obesity and diabetes drug Ozempic to face approval delays in China, where semaglutide competitors are lining up.
Why should I care?
For markets: Health care is acting defensive and stock-picky at once.
Big single-day jumps in Oscar, CVS, and DaVita show how earnings can create wide gaps between winners and laggards, even when the broader sector barely moves. That matters for anyone holding broad funds like the Health Care Select Sector SPDR Fund (XLV) – the headline return can mask a lot of churn underneath. It also hints that investors are rewarding firms that can prove two things at the same time: steady demand and credible cost control.
The bigger picture: Generic timing is increasingly shaped by regulators, not just patents.
Novo’s China update is a reminder that “when a patent expires” isn’t always “when prices fall.” Approval can hinge on regulatory exclusivity – protections that stop rivals from using a company’s clinical trial data for a period of time – and on trade agreements that extend those protections. If semaglutide generics really are pushed out, it reinforces a wider pattern in pharma: policy and paperwork can be as important as science in deciding how fast competition arrives.